216 related articles for article (PubMed ID: 20054414)
1. Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.
Smid SD
Clin Ophthalmol; 2009; 3():663-70. PubMed ID: 20054414
[TBL] [Abstract][Full Text] [Related]
2. Prostamides (prostaglandin-ethanolamides) and their pharmacology.
Woodward DF; Liang Y; Krauss AH
Br J Pharmacol; 2008 Feb; 153(3):410-9. PubMed ID: 17721551
[TBL] [Abstract][Full Text] [Related]
3. A historical perspective and recent advances in prostamide research and therapeutics.
Burk RM; Woodward DF
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):413-21. PubMed ID: 17659482
[TBL] [Abstract][Full Text] [Related]
4. Bimatoprost: a novel antiglaucoma agent.
Woodward DF; Phelps RL; Krauss AH; Weber A; Short B; Chen J; Liang Y; Wheeler LA
Cardiovasc Drug Rev; 2004; 22(2):103-20. PubMed ID: 15179448
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression.
Liang Y; Li C; Guzman VM; Evinger AJ; Protzman CE; Krauss AH; Woodward DF
J Biol Chem; 2003 Jul; 278(29):27267-77. PubMed ID: 12724323
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of bimatoprost (Lumigan).
Woodward DF; Krauss AH; Chen J; Lai RK; Spada CS; Burk RM; Andrews SW; Shi L; Liang Y; Kedzie KM; Chen R; Gil DW; Kharlamb A; Archeampong A; Ling J; Madhu C; Ni J; Rix P; Usansky J; Usansky H; Weber A; Welty D; Yang W; Tang-Liu DD; Garst ME; Brar B; Wheeler LA; Kaplan LJ
Surv Ophthalmol; 2001 May; 45 Suppl 4():S337-45. PubMed ID: 11434936
[TBL] [Abstract][Full Text] [Related]
7. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management.
Cantor LB
Expert Opin Investig Drugs; 2001 Apr; 10(4):721-31. PubMed ID: 11281821
[TBL] [Abstract][Full Text] [Related]
8. Cellular basis for bimatoprost effects on human conventional outflow.
Stamer WD; Piwnica D; Jolas T; Carling RW; Cornell CL; Fliri H; Martos J; Pettit SN; Wang JW; Woodward DF
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5176-81. PubMed ID: 20435598
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of bimatoprost.
Cantor LB
Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):151-7. PubMed ID: 16922657
[TBL] [Abstract][Full Text] [Related]
10. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products.
Woodward DF; Carling RW; Cornell CL; Fliri HG; Martos JL; Pettit SN; Liang Y; Wang JW
Pharmacol Ther; 2008 Oct; 120(1):71-80. PubMed ID: 18700152
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics.
Woodward DF; Wang JW; Poloso NJ
Pharmacol Rev; 2013; 65(4):1135-47. PubMed ID: 23893067
[TBL] [Abstract][Full Text] [Related]
12. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.
Sharif NA; Kelly CR; Crider JY
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):715-21. PubMed ID: 12556403
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism.
Matias I; Chen J; De Petrocellis L; Bisogno T; Ligresti A; Fezza F; Krauss AH; Shi L; Protzman CE; Li C; Liang Y; Nieves AL; Kedzie KM; Burk RM; Di Marzo V; Woodward DF
J Pharmacol Exp Ther; 2004 May; 309(2):745-57. PubMed ID: 14757851
[TBL] [Abstract][Full Text] [Related]
14. [Receptors involved in the mechanism of action of topical prostaglandines].
Neacsu AM
Oftalmologia; 2009; 53(2):3-7. PubMed ID: 19697832
[TBL] [Abstract][Full Text] [Related]
15. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide.
Richter M; Krauss AH; Woodward DF; Lütjen-Drecoll E
Invest Ophthalmol Vis Sci; 2003 Oct; 44(10):4419-26. PubMed ID: 14507888
[TBL] [Abstract][Full Text] [Related]
16. Bimatoprost, prostamide activity, and conventional drainage.
Wan Z; Woodward DF; Cornell CL; Fliri HG; Martos JL; Pettit SN; Wang JW; Kharlamb AB; Wheeler LA; Garst ME; Landsverk KJ; Struble CS; Stamer WD
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4107-15. PubMed ID: 17724194
[TBL] [Abstract][Full Text] [Related]
17. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences.
Bean GW; Camras CB
Surv Ophthalmol; 2008 Nov; 53 Suppl1():S69-84. PubMed ID: 19038626
[TBL] [Abstract][Full Text] [Related]
18. Granulomatous anterior uveitis associated with bimatoprost: a case report.
Parentin F
Ocul Immunol Inflamm; 2003 Mar; 11(1):67-71. PubMed ID: 12854029
[TBL] [Abstract][Full Text] [Related]
19. Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells.
Spada CS; Krauss AH; Woodward DF; Chen J; Protzman CE; Nieves AL; Wheeler LA; Scott DF; Sachs G
Exp Eye Res; 2005 Jan; 80(1):135-45. PubMed ID: 15652534
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
Sharif NA; Kelly CR; Crider JY; Williams GW; Xu SX
J Ocul Pharmacol Ther; 2003 Dec; 19(6):501-15. PubMed ID: 14733708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
